Results 201 to 210 of about 59,140 (257)

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

New England Journal of Medicine, 2005
Nazzareno Galie, Adam Torbicki, Lewis J Rubin   +2 more
exaly   +2 more sources

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

New England Journal of Medicine, 2018
Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusion ...
Martin R J Kolb, Ganesh Raghu, Athol U Wells   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Oral Sildenafil in the Treatment of Erectile Dysfunction

50 Studies Every Urologist Should Know, 2021
This chapter summarizes the results of a landmark trial comparing different doses of oral sildenafil versus placebo to treat erectile dysfunction. Patients received either an identical placebo or 25- mg, 50-mg, or 100-mg tablets of sildenafil to be taken
J. Bodie
semanticscholar   +1 more source

Sildenafil

Journal of Sex & Marital Therapy, 1999
Case reports have documented the utility of sildenafil for sexual dysfunction caused by selective serotonin-reuptake inhibitors (SSRIs) and have suggested its potential utility for women and men with various iatrogenic sexual dysfunctions. This brief review summarizes the psychopharmacology of sildenafil, discusses possible interactions with SSRIs ...
J, Cartledge, I, Eardley
  +6 more sources

A novel role of Nano selenium and sildenafil on streptozotocin-induced diabetic nephropathy in rats by modulation of inflammatory, oxidative, and apoptotic pathways.

Life Science, 2022
AIMS The present study aimed to investigate the effect of nano selenium, sildenafil, and their combination on inflammation, oxidative stress, and apoptosis in streptozotocin-induced diabetic nephropathy in rats.
M. El-Azab, A. Al-karmalawy, S. Antar, Pierre Hanna, Karima Tawfik, Reem M. Hazem   +5 more
semanticscholar   +1 more source

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications

Fundamental & Clinical Pharmacology, 2020
Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertension (PAH).
Moein Ala, Razieh Mohammad Jafari, A. Dehpour   +2 more
semanticscholar   +1 more source

The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction.

Sexual Medicine Reviews, 2019
INTRODUCTION The serendipitous discovery of sildenafil (Viagra [sildenafil citrate]) as a treatment for erectile dysfunction (ED) is one of the most fascinating drug development stories of our time. When sildenafil was approved by the U.S.
I. Goldstein, A. Burnett, R. Rosen, P. Park, V. Stecher   +4 more
semanticscholar   +1 more source

Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.

Journal of Controlled Release, 2019
Pulmonary delivery of vasodilators is a promising alternative for the intravenous and oral treatment of pulmonary arterial hypertension (PAH). The aim of this study was to design and evaluate hydrogel microparticles as a carrier for sustained pulmonary ...
Hend I. Shahin, Bhavani Prasad Vinjamuri, Azza A K Mahmoud, R. Shamma, S. Mansour, H. Ammar, M. Ghorab, M. Chougule, L. Chablani   +8 more
semanticscholar   +1 more source